{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:15:18Z","timestamp":1793776518298,"version":"4.6.1"},"reference-count":84,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2020,5,26]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Vaccination is one of the most effective and cost-efficient methods for protecting people with multiple sclerosis (MS) from infections. However, use of vaccines has often been problematic because of misguided concerns that they may exacerbate the disease and\/or that some disease-modifying therapies may influence the immune response to immunisations and\/or their safety. People with MS risk higher morbidity and mortality from vaccine-preventable infections. It is, therefore, important to address any patient\u2019s reluctance to accept vaccination and to provide clear guidance for clinicians on which vaccinations to consider proactively. We have reviewed the current literature and provide recommendations regarding vaccines in adults with MS, including specific advice regarding vaccination safety in patients receiving\u2014or going to receive\u2014disease-modifying therapies, vaccination during pregnancy, pretravel counselling and patient education.<\/jats:p>","DOI":"10.1136\/practneurol-2020-002527","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T17:25:30Z","timestamp":1594056330000},"page":"435.1-445","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["Protecting people with multiple sclerosis through vaccination"],"prefix":"10.1136","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3230-3263","authenticated-orcid":false,"given":"Sa\u00fal","family":"Reyes","sequence":"first","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"},{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Immunisation and Countermeasures Division, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez","family":"Ladhani","sequence":"additional","affiliation":[{"name":"Immunisation and Countermeasures Division, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Amirthalingam","sequence":"additional","affiliation":[{"name":"Immunisation and Countermeasures Division, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cores","sequence":"additional","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"joela","family":"Mathews","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lambourne","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9070","authenticated-orcid":false,"given":"Monica","family":"Marta","sequence":"additional","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"},{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-2357","authenticated-orcid":false,"given":"Benjamin","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"},{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"},{"name":"Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"},{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"G","family":"Giovannoni","sequence":"additional","affiliation":[{"name":"Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, London, UK"},{"name":"Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2025090411002417000_20.6.435.1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24657"},{"key":"2025090411002417000_20.6.435.2","unstructured":"Peckham CA . The Peckham report: National immunisation study: factors influencing immunisation uptake in childhood . London: The Department of Paediatric epidemiology, Institute of Child Health, 1989."},{"key":"2025090411002417000_20.6.435.3","unstructured":"England PH . Immunisation against infectious disease (The Green Book) . The Stationery Office: London, 2017."},{"key":"2025090411002417000_20.6.435.4","unstructured":"England PH . PHE offers support to UK vaccine heroes. 2019. Available https:\/\/www.gov.uk\/government\/news\/phe-offers-support-to-uk-vaccine-heroes (accessed 26 Oct 2019)"},{"key":"2025090411002417000_20.6.435.5","unstructured":"National Health Service Digital . Childhood vaccination coverage statistics - England 2018\u201319. Available https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/nhs-immunisation-statistics\/england-2018-19 (accessed 13 Dec 2019)"},{"key":"2025090411002417000_20.6.435.6","unstructured":"Public Health England . Measles cases in England: January to December 2018. 2019. Available https:\/\/www.gov.uk\/government\/publications\/measles-mumps-and-rubella-laboratory-confirmed-cases-in-england-2018\/measles-cases-in-england-january-to-december-2018 (accessed 9 Dec 2019)"},{"key":"2025090411002417000_20.6.435.7","unstructured":"Public Health England . Seasonal flu vaccine uptake in GP patients: monthly data, 2018 to 2019. 2019. Available https:\/\/www.gov.uk\/government\/statistics\/seasonal-flu-vaccine-uptake-in-gp-patients-monthly-data-2018-to-2019 (accessed 26 Oct 2019)"},{"key":"2025090411002417000_20.6.435.8","unstructured":"Public Health England . Herpes zoster (shingles) immunisation programme 2017 to 2018: evaluation report. 2018. Available https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/758888\/hpr4218_shngls_vc.pdf (accessed 20 Jun 2019)"},{"key":"2025090411002417000_20.6.435.9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal controversies in vaccine safety in the United States","volume":"69","author":"DeStefano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025090411002417000_20.6.435.10","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.4.504"},{"key":"2025090411002417000_20.6.435.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-5984-2"},{"key":"2025090411002417000_20.6.435.12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","article-title":"Vaccines and multiple sclerosis: a systematic review","volume":"264","author":"Mailand","year":"2017","journal-title":"J Neurol"},{"key":"2025090411002417000_20.6.435.13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ane.12837","article-title":"Vaccines and multiple sclerosis","volume":"136","author":"Mailand","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"2025090411002417000_20.6.435.14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol"},{"key":"2025090411002417000_20.6.435.15","doi-asserted-by":"crossref","first-page":"e908","DOI":"10.1212\/WNL.0000000000008012","article-title":"A large case-control study on vaccination as risk factor for multiple sclerosis","volume":"93","author":"Hapfelmeier","year":"2019","journal-title":"Neurology"},{"key":"2025090411002417000_20.6.435.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440501"},{"key":"2025090411002417000_20.6.435.17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"2025090411002417000_20.6.435.18","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.131"},{"key":"2025090411002417000_20.6.435.19","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.1519"},{"key":"2025090411002417000_20.6.435.20","doi-asserted-by":"crossref","first-page":"e726","DOI":"10.1212\/NXI.0000000000000726","article-title":"Risk of MS relapse after yellow fever vaccination","volume":"7","author":"Huttner","year":"2020","journal-title":"Neurol - Neuroimmunol NeuroInflammation"},{"key":"2025090411002417000_20.6.435.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.7.938"},{"key":"2025090411002417000_20.6.435.22","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513513970"},{"key":"2025090411002417000_20.6.435.23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/ene.13537","article-title":"Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy","volume":"25","author":"Olberg","year":"2018","journal-title":"Eur J Neurol"},{"key":"2025090411002417000_20.6.435.24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12132"},{"key":"2025090411002417000_20.6.435.25","doi-asserted-by":"crossref","first-page":"e78532","DOI":"10.1371\/journal.pone.0078532","article-title":"Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFN\u03b2-therapy","volume":"8","author":"Mehling","year":"2013","journal-title":"PLoS One"},{"key":"2025090411002417000_20.6.435.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir007"},{"key":"2025090411002417000_20.6.435.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.8"},{"key":"2025090411002417000_20.6.435.28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy174"},{"key":"2025090411002417000_20.6.435.29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518823940"},{"key":"2025090411002417000_20.6.435.30","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000233834.09743.3b"},{"key":"2025090411002417000_20.6.435.31","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf098"},{"key":"2025090411002417000_20.6.435.32","unstructured":"Datapharm Ltd. Electronic medicines compendium (EMC). Available https:\/\/www.medicines.org.uk\/emc (accessed 26 Oct 2019)"},{"key":"2025090411002417000_20.6.435.33","unstructured":"Public Health England . Complete routine immunisation schedule. 2019. Available https:\/\/www.gov.uk\/government\/publications\/the-complete-routine-immunisation-schedule (accessed 25 Jun 2019)"},{"key":"2025090411002417000_20.6.435.34","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2018.10.017","article-title":"Vaccines and disease-modifying treatments","volume":"26","author":"Waubant","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2025090411002417000_20.6.435.35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WCO.0000000000000561","article-title":"Disease-modifying treatments for early and advanced multiple sclerosis","volume":"31","author":"Giovannoni","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"2025090411002417000_20.6.435.36","doi-asserted-by":"crossref","first-page":"S36.002","DOI":"10.1212\/WNL.90.15_supplement.S36.002","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis","volume":"90","author":"Stokmaier","year":"2018","journal-title":"Neurology"},{"key":"2025090411002417000_20.6.435.37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","article-title":"Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports","volume":"35","author":"Croce","year":"2017","journal-title":"Vaccine"},{"key":"2025090411002417000_20.6.435.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30600-5"},{"key":"2025090411002417000_20.6.435.39","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"2025090411002417000_20.6.435.40","first-page":"e326","article-title":"P 2 effect of ocrelizumab on humoral immunity markers in the phase III, double-blind, double-dummy, IFN \u03b2 \u22121a: Controlled OPERA I and OPERA II studies","volume":"128","author":"Ziemssen","year":"2017","journal-title":"Clin Neurophysiol"},{"key":"2025090411002417000_20.6.435.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a35215"},{"key":"2025090411002417000_20.6.435.42","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000188901.12700.e0"},{"key":"2025090411002417000_20.6.435.43","doi-asserted-by":"crossref","unstructured":"Von Hehn C , Howard J , Liu S , et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol NeuroInflammation 2018;5. doi: doi:10.1212\/NXI.0000000000000409","DOI":"10.1212\/NXI.0000000000000409"},{"key":"2025090411002417000_20.6.435.44","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/NXI.0000000000000070","article-title":"Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens","volume":"2","author":"Bar-Or","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"2025090411002417000_20.6.435.45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829e6fbf"},{"key":"2025090411002417000_20.6.435.46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001302"},{"key":"2025090411002417000_20.6.435.47","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011427908"},{"key":"2025090411002417000_20.6.435.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.03.035"},{"key":"2025090411002417000_20.6.435.49","unstructured":"Centers for Disease Control and Prevention (CDC) . ACIP general best guidance for immunization: altered immunocompetence. 2019. Available https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.html (accessed 24 Oct 2019)"},{"key":"2025090411002417000_20.6.435.50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/irv.12533","article-title":"Advances in measuring influenza burden of disease","volume":"12","author":"Lee","year":"2018","journal-title":"Influenza Other Respi Viruses"},{"key":"2025090411002417000_20.6.435.51","doi-asserted-by":"publisher","DOI":"10.1086\/500140"},{"key":"2025090411002417000_20.6.435.52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.12.1837"},{"key":"2025090411002417000_20.6.435.53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ287"},{"key":"2025090411002417000_20.6.435.54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025090411002417000_20.6.435.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.12.024"},{"key":"2025090411002417000_20.6.435.56","unstructured":"Centers for Disease Control and Prevention (CDC) . Shingrix recommendations. 2018. Available https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/recommendations.html (accessed 22 Apr 2019)"},{"key":"2025090411002417000_20.6.435.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.03.018"},{"key":"2025090411002417000_20.6.435.58","unstructured":"Centers for Disease Control and Prevention (CDC) . ACIP general best guidance for immunization: timing and spacing of immunobiologics. 2019. Available https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html#t-03 (accessed 26 Oct 2019)"},{"key":"2025090411002417000_20.6.435.59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"2025090411002417000_20.6.435.60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pvr.2017.06.002","article-title":"HPV vaccination of immunocompromised hosts","volume":"4","author":"Garland","year":"2017","journal-title":"Papillomavirus Res (Amsterdam, Netherlands)"},{"key":"2025090411002417000_20.6.435.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2009.11.027"},{"key":"2025090411002417000_20.6.435.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"2025090411002417000_20.6.435.63","doi-asserted-by":"crossref","unstructured":"Arbyn M , Xu L , Simoens C , et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;2018. doi: doi:10.1002\/14651858.CD009069.pub3","DOI":"10.1002\/14651858.CD009069.pub3"},{"key":"2025090411002417000_20.6.435.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.069"},{"key":"2025090411002417000_20.6.435.65","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.32700","article-title":"Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study","volume":"126","author":"Rodriguez","year":"2020","journal-title":"Cancer"},{"key":"2025090411002417000_20.6.435.66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388892"},{"key":"2025090411002417000_20.6.435.67","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett","year":"2019","journal-title":"Mult Scler J"},{"key":"2025090411002417000_20.6.435.68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62352-5"},{"key":"2025090411002417000_20.6.435.69","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.77a.09123"},{"key":"2025090411002417000_20.6.435.70","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2019-208490"},{"key":"2025090411002417000_20.6.435.71","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8303-9"},{"key":"2025090411002417000_20.6.435.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.09.034"},{"key":"2025090411002417000_20.6.435.73","unstructured":"Public Health England . Laboratory confirmed cases of pertussis reported to the enhanced pertussis surveillance programme in England: annual report for 2013. 2014. Available https:\/\/www.gov.uk\/government\/publications\/pertussis-enhanced-surveillance-laboratory-confirmed-cases-in-england-in-2013\/laboratory-confirmed-cases-of-pertussis-reported-to-the-enhanced-pertussis-surveillance-programme-in-england-annual-report-for-2013 (accessed 23 May 2019)"},{"key":"2025090411002417000_20.6.435.74","unstructured":"Department of Health and Social Care . Whooping cough vaccination programme for pregnant women. 2012. Available https:\/\/www.gov.uk\/government\/publications\/whooping-cough-vaccination-programme-for-pregnant-women (accessed 25 May 2020)"},{"key":"2025090411002417000_20.6.435.75","first-page":"1424","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <2 months: ACIP, 2011","volume":"60","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"2025090411002417000_20.6.435.76","first-page":"620","article-title":"The pretravel consultation","volume":"94","author":"Sanford","year":"2016","journal-title":"Am Fam Physician"},{"key":"2025090411002417000_20.6.435.77","unstructured":"National Travel Health Network and Centre (NaTHNaC) . TravelHealthPro. Available https:\/\/travelhealthpro.org.uk\/countries (accessed 23 Apr 2019)"},{"key":"2025090411002417000_20.6.435.78","unstructured":"World Health Organization (WHO ). Statement of the twenty-third IHR Emergency Committee regarding the international spread of poliovirus. 2020. Available https:\/\/www.who.int\/news-room\/detail\/20-12-2019-statement-o-the-twenty-third-ihr-emergency-committee-regarding-the-international-spread-of-poliovirus (accessed 15 Apr 2020)"},{"key":"2025090411002417000_20.6.435.79","unstructured":"World Health Organization (WHO) . Ten threats to global health in 2019. 2019. Available https:\/\/www.who.int\/emergencies\/ten-threats-to-global-health-in-2019 (accessed 26 Oct 2019)"},{"key":"2025090411002417000_20.6.435.80","unstructured":"World Health Organization (WHO ). Report of the SAGE Working Group on Vaccine Hesitancy. 2014. Available https:\/\/www.who.int\/immunization\/programmes_systems\/vaccine_hesitancy\/en\/ (accessed 23 Apr 2019)"},{"key":"2025090411002417000_20.6.435.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.081"},{"key":"2025090411002417000_20.6.435.82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M18-2101","article-title":"Measles, mumps, rubella vaccination and autism: a nationwide cohort study","volume":"170","author":"Hviid","year":"2019","journal-title":"Ann Intern Med"},{"key":"2025090411002417000_20.6.435.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.06.028"},{"key":"2025090411002417000_20.6.435.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.038"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2020-002527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:04:28Z","timestamp":1757009068000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2020-002527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/practneurol-2020-002527"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2020-002527","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}